JPMorgan Chase & Co. set a CHF 78 price target on Novartis (VTX:NOVN) in a research note published on Thursday morning, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.

NOVN has been the subject of several other research reports. Barclays set a CHF 75 target price on shares of Novartis and gave the stock a sell rating in a research note on Friday, February 1st. Credit Suisse Group set a CHF 84 target price on shares of Novartis and gave the stock a neutral rating in a research note on Friday, April 5th. Jefferies Financial Group set a CHF 95 target price on shares of Novartis and gave the stock a buy rating in a research note on Wednesday, April 17th. Kepler Capital Markets set a CHF 87 target price on shares of Novartis and gave the stock a buy rating in a research note on Tuesday, May 21st. Finally, Goldman Sachs Group set a CHF 98 target price on shares of Novartis and gave the stock a buy rating in a research note on Wednesday, April 24th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of Hold and an average price target of CHF 89.06.

Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

See Also: Options Trading – Understanding Strike Price

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.